Atai Life Sciences Statistics
Share Statistics
Atai Life Sciences has 200.34M
shares outstanding. The number of shares has increased by 18.46%
in one year.
| Shares Outstanding | 200.34M |
| Shares Change (YoY) | 18.46% |
| Shares Change (QoQ) | 18.18% |
| Owned by Institutions (%) | 9.05% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 25,234 |
| FTD / Avg. Volume | 1.34% |
Short Selling Information
The latest short interest is 12.79M, so 6.38% of the outstanding
shares have been sold short.
| Short Interest | 12.79M |
| Short % of Shares Out | 6.38% |
| Short % of Float | 8.34% |
| Short Ratio (days to cover) | 10.23 |
Valuation Ratios
The PE ratio is -1.43 and the forward
PE ratio is -3.68.
Atai Life Sciences's PEG ratio is
-0.01.
| PE Ratio | -1.43 |
| Forward PE | -3.68 |
| PS Ratio | 691.6 |
| Forward PS | 0.9 |
| PB Ratio | 1.83 |
| P/FCF Ratio | -2.58 |
| PEG Ratio | -0.01 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Atai Life Sciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.21,
with a Debt / Equity ratio of 0.21.
| Current Ratio | 3.21 |
| Quick Ratio | 3.21 |
| Debt / Equity | 0.21 |
| Debt / EBITDA | -0.17 |
| Debt / FCF | -0.3 |
| Interest Coverage | -32.87 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $5,703.7 |
| Profits Per Employee | $-2,764,240.74 |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -356K |
| Effective Tax Rate | 0.24% |
Stock Price Statistics
The stock price has increased by 47.13% in the
last 52 weeks. The beta is 1.23, so Atai Life Sciences's
price volatility has been higher than the market average.
| Beta | 1.23 |
| 52-Week Price Change | 47.13% |
| 50-Day Moving Average | 1.55 |
| 200-Day Moving Average | 1.47 |
| Relative Strength Index (RSI) | 76.68 |
| Average Volume (20 Days) | 1,880,190 |
Income Statement
In the last 12 months, Atai Life Sciences had revenue of 308K
and earned -149.27M
in profits. Earnings per share was -0.93.
| Revenue | 308K |
| Gross Profit | 1.55M |
| Operating Income | -102.69M |
| Net Income | -149.27M |
| EBITDA | -145.33M |
| EBIT | -145.28M |
| Earnings Per Share (EPS) | -0.93 |
Full Income StatementBalance Sheet
The company has 17.5M in cash and 24.71M in
debt, giving a net cash position of -7.2M.
| Cash & Cash Equivalents | 17.5M |
| Total Debt | 24.71M |
| Net Cash | -7.2M |
| Retained Earnings | -700.21M |
| Total Assets | 195.78M |
| Working Capital | 87.48M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -82.44M
and capital expenditures -95K, giving a free cash flow of -82.53M.
| Operating Cash Flow | -82.44M |
| Capital Expenditures | -95K |
| Free Cash Flow | -82.53M |
| FCF Per Share | -0.52 |
Full Cash Flow StatementMargins
Gross margin is 504.87%, with operating and profit margins of -33341.23% and -48463.96%.
| Gross Margin | 504.87% |
| Operating Margin | -33341.23% |
| Pretax Margin | -48183.44% |
| Profit Margin | -48463.96% |
| EBITDA Margin | -47186.04% |
| EBIT Margin | -33341.23% |
| FCF Margin | -26796.1% |
